AMY STOTT: Open Payments
NPI 1427420397 · NEWBURGH, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,516 in 88 payments from 15 companies in 2025. Trend: 2023 $1,607 · 2024 $1,495 · 2025 $1,516
Food & beverage: $1,516
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 32 | $520 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 14 | $250 |
| Ardelyx, Inc. | 14 | $200 |
| Janssen Biotech, Inc. | 4 | $102 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $75 |
| Phathom Pharmaceuticals, Inc. | 6 | $70 |
| Gilead Sciences, Inc. | 3 | $65 |
| Lilly USA, LLC | 3 | $47 |
| Aimmune Therapeutics, Inc. | 2 | $43 |
| GENZYME CORPORATION | 1 | $34 |
Products named: RINVOQ, XIFAXAN, IBSRELA, TREMFYA, MAVYRET, VOQUEZNA, VIBERZI, DUPIXENT.
Industry payments across IN — which companies pay providers there.
